Neurocognitive and neuropsychiatric symptoms are essential clinical manifestations of age-related cognitive impairment, yet their patterns of co-existence remain unclear through the cognitive continuum.
Objective
To examine the associations of person-centered cluster-derived patterns, based on a comprehensive collection of domain-specific cognitive and neuropsychiatric assessments, with neuroimaging markers and dementia risk.
Methods
641 participants were included in the analysis from memory clinics in Singapore. Latent class analysis was applied to define clusters of individuals with different clinical patterns. The associations between identified clinical groups with neuroimaging markers of cerebrovascular diseases and neurodegeneration were analyzed using logistic regression models. Cox proportional hazard models were applied for incident dementia.
Results
Three latent classes differing in neurocognitive and neuropsychiatric impairment were identified (Class 1 “memory impairment only”; Class 2 “global cognitive impairment”; Class 3 “global cognitive and neuropsychiatric impairment”). Compared with Class 1, Class 2 and 3 were associated with smaller brain volumes, moderate-to-severe cortical atrophy and medial temporal lobe atrophy, and the presence of all cerebrovascular lesions. Moreover, compared with Class 2, Class 3 had smaller brain volumes, moderate-to-severe cortical atrophy and presence of intracranial stenosis. Additionally, compared to Class 1, Class 2 (hazard ratio [HR] = 3.84, 95%CI 2.11–7.00), and Class 3 (HR = 6.92, 95%CI 2.84–16.83) showed an increased risk of incident dementia.
Conclusions
Participants characterized by multi-domain cognitive impairment and co-occurrence of cognitive and neuropsychiatric impairment showed the highest risk of incident dementia, which may be attributed to both neurodegenerative and cerebrovascular pathologies.
EikelboomWSBergESingletonEH, et al.Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum: cross-sectional and longitudinal associations. Neurology2021; 97: e1276–e1287.
2.
HanssonO. Biomarkers for neurodegenerative diseases. Nat Med2021; 27: 954–963.
3.
Krell-RoeschJSyrjanenJAMachuldaMM, et al.Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: the Mayo Clinic Study of Aging. Int J Geriatr Psychiatry2021; 36: 1362–1369.
4.
LüWDuanJZhangW, et al.Relationship between neuropsychiatric symptoms and cognitive functions in patients with cognitive impairment. Psychogeriatrics2021; 21: 773–782.
5.
JohanssonMStomrudEJohanssonPM, et al.Development of apathy, anxiety, and depression in cognitively unimpaired older adults: effects of Alzheimer's disease pathology and cognitive decline. Biol Psychiatry2022; 92: 34–43.
6.
ChanCKPettigrewCSoldanA, et al.Association between late-life neuropsychiatric symptoms and cognitive decline in relation to white matter hyperintensities and amyloid burden. J Alzheimers Dis2022; 86: 1415–1426.
7.
MisquittaKDadarMLouis CollinsD, et al.White matter hyperintensities and neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease. Neuroimage Clin2020; 28: 102367.
8.
ThomasKRBangenKJWeigandAJ, et al.Cognitive heterogeneity and risk of progression in data-driven subtle cognitive decline phenotypes. J Alzheimers Dis2022; 90: 323–331.
9.
RobertoNPortellaMJMarquiéM, et al.Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. Sci Rep2021; 11: 6448.
10.
LiewTMYuJMahendranR, et al.Neuropsychiatric and cognitive subtypes among community-dwelling older persons and the association with DSM-5 mild neurocognitive disorder: latent class analysis. J Alzheimers Dis2018; 62: 675–686.
11.
BrickmanAMTostoGGutierrezJ, et al.An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease. Neurology2018; 91: e1402–e1412.
12.
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet2001; 357: 169–175.
13.
KapasiADeCarliCSchneiderJA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol2017; 134: 171–186.
14.
OzzoudeMVarrianoBBeatonD, et al.White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases. Alzheimers Res Ther2023; 15: 114.
15.
NarasimhaluKAngSSilvaD, et al.Severity of CIND and MCI predict incidence of dementia in an ischemic stroke cohort. Neurology2009; 73: 1866–1872.
16.
XuXChanYHChanQL, et al.Global cerebrovascular burden and long-term clinical outcomes in Asian elderly across the spectrum of cognitive impairment. Int Psychogeriatr2018; 30: 1355–1363.
17.
Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association, 2000.
18.
D’EliaLSatzPUchiyamaC, et al.Color Trails Test Professional Manual. Odessa, FL: Psychological Assessment Resources, 1996.
19.
McKhannGDrachmanDFolsteinM, et al.Clinical diagnosis of Alzheimer’s disease report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology1984; 34: 939–939.
20.
MackWJFreedDMWilliamsBW, et al.Boston Naming test: shortened versions for use in Alzheimer’s disease. J Gerontol1992; 47: P154–P158.
21.
SmithA. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services, 1973.
22.
MeyersJEMeyersKR. Rey Complex Figure Test and Recognition Trial. Odessa, FL: Psychological Assessment Resources, 1994.
23.
SahadevanSTanNJTanTC, et al.Cognitive testing of elderly Chinese from selected community clubs in Singapore. Ann Acad Med Singapore1997; 26: 271–277.
CummingsJL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology1997; 48: S10–S16.
26.
van VeluwSJHilalSKuijfHJ, et al.Cortical microinfarcts on 3T MRI: clinical correlates in memory-clinic patients. Alzheimers Dement2015; 11: 1500–1509.
27.
VroomanHACocoscoCAvan der LijnF, et al.Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. Neuroimage2007; 37: 71–81.
28.
HilalSChaiYLIkramMK, et al.Markers of cardiac dysfunction in cognitive impairment and dementia. Medicine (Baltimore)2015; 94: e297.
29.
WardlawJMSmithEEBiesselsGJ, et al.Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol2013; 12: 822–838.
30.
HilalSSainiMTanCS, et al.Intracranial stenosis, cerebrovascular diseases, and cognitive impairment in Chinese. Alzheimer Dis Assoc Disord2015; 29: 12–17.
31.
FazekasFKleinertROffenbacherH, et al.Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology1993; 43: 1683.
32.
CordonnierCPotterGMJacksonCA, et al.Improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke2009; 40: 94–99.
33.
KorfESWahlundLOVisserPJ, et al.Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology2004; 63: 94–100.
34.
WattjesMPHennemanWJFlierWM, et al.Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. Radiology2009; 253: 174–183.
HagenaarsJMMcCutcheonAL. Applied Latent Class Analysis. Cambridge: Cambridge University Press, 2002.
37.
ChwarzG. Estimating the dimension of a model. Ann Stat1978; 6: 461–464.
38.
ScloveSL. Application of model-selection criteria to some problems in multivariate analysis. Psychometrika1987; 52: 333–343.
39.
WellerBEBowenNKFaubertSJ. Latent class analysis: a guide to best practice. J Black Psychol2020; 46: 287–311.
40.
BrowningCAThompsonCLKochanNA, et al.Prospective memory function predicts future cognitive decline and incident dementia. J Gerontol B Psychol Sci Soc Sci2023; 78: 819–829.
41.
JangJYHoJKBlankenAE, et al.Affective neuropsychiatric symptoms as early signs of dementia risk in older adults. J Alzheimers Dis2020; 77: 1195–1207.
42.
AkoudadSWoltersFJViswanathanA, et al.Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol2016; 73: 934–943.
43.
HanseeuwBJJacobsHILSchultzAP, et al.Association of pathologic and volumetric biomarker changes with cognitive decline in clinically normal adults. Neurology2023; 101: e2533–e2544.
44.
HilalSXuXIkramMK, et al.Intracranial stenosis in cognitive impairment and dementia. J Cereb Blood Flow Metab2017; 37: 2262–2269.
45.
PerneczkyRWagenpfeilSLunettaKL, et al.Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. Neurology2010; 75: 137–142.
46.
OttoyJOzzoudeMZukotynskiK, et al.Vascular burden and cognition: mediating roles of neurodegeneration and amyloid PET. Alzheimers Dement2023; 19: 1503–1517.
47.
LegdeurNVisserPJWoodworthDC, et al.White matter hyperintensities and hippocampal atrophy in relation to cognition: the 90+ Study. J Am Geriatr Soc2019; 67: 1827–1834.
48.
ProsserLMacdougallASudreCH, et al.Predicting cognitive decline in older adults using baseline metrics of AD pathologies, cerebrovascular disease, and neurodegeneration. Neurology2023; 100: e834–e845.
49.
TanCHHilalSXuX, et al.MRI Markers of mixed pathology and cognitive impairment in multiethnic Asians. J Alzheimers Dis2020; 73: 1501–1509.
50.
PohLFannDYWongP, et al.AIM2 Inflammasome mediates hallmark neuropathological alterations and cognitive impairment in a mouse model of vascular dementia. Mol Psychiatry2021; 26: 4544–4560.
51.
GuoYSunYLiM, et al.Amyloid pathology modulates the associations of neuropsychiatric symptoms with cognitive impairments and neurodegeneration in non-demented elderly. J Alzheimers Dis2024; 97: 471–484.
52.
De LuciaNCarboneGMuziiB, et al.Neuropsychiatric symptoms and their neural correlates in individuals with mild cognitive impairment. Int Psychogeriatr2023; 35: 623–632.
53.
GroolAMGeerlingsMISigurdssonS, et al.Structural MRI correlates of apathy symptoms in older persons without dementia: AGES-Reykjavik Study. Neurology2014; 82: 1628–1635.
54.
NgKPChiewHRosa-NetoP, et al.Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. Transl Neurodegener2021; 10: 11.
LevyRDuboisB. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex2006; 16: 916–928.
57.
ClancyURamirezJChappellFM, et al.Neuropsychiatric symptoms as a sign of small vessel disease progression in cognitive impairment. Cereb Circ Cogn Behav2022; 3: 100041.
58.
BrayMJCSharmaBCottrelle'sJ, et al.Hippocampal atrophy is associated with psychotic symptom severity following traumatic brain injury. Brain Commun2021; 3: fcab026.
59.
SiafarikasN. Neuropsychiatric and cognitive symptoms: two sides of the same coin?J Alzheimers Dis2024; 98: 75–78.
60.
BruenPDMcGeownWJShanksMF, et al.Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain2008; 131: 2455–2463.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
